Physician profile
Ricky K Hsu
NPI 1568491967
$1,027,899.79
in general payments reported to CMS, 2019-2025
42 companies · $129K in 2025
The $129K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223K · 2020: $104K · 2021: $99K · 2022: $168K · 2023: $165K · 2024: $141K · 2025: $129K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $320K · Travel and Lodging: $48K · Consulting Fee: $44K · Food and Beverage: $17K · Honoraria: $6,250 · Education: $1.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $319,530.00 |
| Travel and Lodging | $48,179.73 |
| Consulting Fee | $43,872.76 |
| Food and Beverage | $16,624.69 |
| Honoraria | $6,250.00 |
| Education | $1.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $663,707.07 | 2019-2025 | Cabenuva, Dovato, Rukobia |
| Janssen Products, Lp | $104,816.49 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $83,736.21 | 2019-2025 | Pifeltro, Delstrigo, Capvaxive |
| Gilead Sciences, INC. | $76,768.75 | 2019-2025 | Biktarvy, Descovy, Veklury |
| Emd Serono, INC. | $72,087.94 | 2019-2025 | Serostim, Serostim |
| Janssen Scientific Affairs, LLC | $8,408.83 | 2019-2023 | Xarelto, Symtuza |
| Theratechnologies INC. | $8,276.51 | 2019-2025 | Egrifta, Trogarzo |
| Roche Diagnostics International Ltd | $4,144.00 | 2022 | |
| Janssen Biotech, INC. | $1,502.70 | 2019-2023 | Symtuza |
| Glaxosmithkline, LLC. | $1,147.77 | 2019-2021 | |
| Abbvie INC. | $580.12 | 2019-2025 | |
| Bausch Health US, LLC | $316.82 | 2020-2025 | Wellbutrin, Aplenzin |
| Allergan, INC. | $238.74 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $216.66 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.65 | 2019-2025 | Xifaxan, Trulance, Relistor |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricky Hsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.